These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 3097716)
1. Behavioral and physiological effects associated with changes in muscarinic receptors following administration of an irreversible cholinergic agonist (BM 123). Russell RW; Smith CA; Booth RA; Jenden DJ; Waite JJ Psychopharmacology (Berl); 1986; 90(3):308-15. PubMed ID: 3097716 [TBL] [Abstract][Full Text] [Related]
2. Behavioral and physiological effects of an aziridinium analog of oxotremorine (BM130). Russell RW; Crocker AD; Booth RA; Jenden DJ Psychopharmacology (Berl); 1986; 88(1):24-32. PubMed ID: 3080775 [TBL] [Abstract][Full Text] [Related]
3. Pretreatment with an irreversible muscarinic agonist affects responses to apomorphine. Crocker AD; Russell RW Pharmacol Biochem Behav; 1990 Mar; 35(3):511-6. PubMed ID: 2339142 [TBL] [Abstract][Full Text] [Related]
4. An alkylating derivative of oxotremorine interacts irreversibly with the muscarinic receptor. Ehlert FJ; Jenden DJ; Ringdahl B Life Sci; 1984 Mar; 34(10):985-91. PubMed ID: 6700365 [TBL] [Abstract][Full Text] [Related]
5. The conversion of 2-chloroalkylamine analogues of oxotremorine to aziridinium ions and their interactions with muscarinic receptors in the guinea pig ileum. Ringdahl B; Resul B; Ehlert FJ; Jenden DJ; Dahlbom R Mol Pharmacol; 1984 Sep; 26(2):170-9. PubMed ID: 6332977 [TBL] [Abstract][Full Text] [Related]
6. Effects of an irreversible muscarinic agonist (BM123) on avoidance and spontaneous alternation performance. Overstreet DH; Booth RA; Jenden DJ Pharmacol Biochem Behav; 1988 Oct; 31(2):337-43. PubMed ID: 3244711 [TBL] [Abstract][Full Text] [Related]
7. Muscarinic actions and receptor binding of the enantiomers of BM 130, an alkylating analog of oxotremorine. Ringdahl B; Katz ED; Roch M; Jenden DJ J Pharmacol Exp Ther; 1989 Apr; 249(1):210-5. PubMed ID: 2709331 [TBL] [Abstract][Full Text] [Related]
8. The binding of a 2-chloroethylamine derivative of oxotremorine (BM 123) to muscarinic receptors in the rat cerebral cortex. Ehlert FJ; Jenden DJ Mol Pharmacol; 1985 Aug; 28(2):107-19. PubMed ID: 3839562 [TBL] [Abstract][Full Text] [Related]
9. BM-5, a centrally active partial muscarinic agonist with low tremorogenic activity. In vivo and in vitro studies. Engström C; Undén A; Ladinsky H; Consolo S; Bartfai T Psychopharmacology (Berl); 1987; 91(2):161-7. PubMed ID: 3107028 [TBL] [Abstract][Full Text] [Related]
10. Muscarinic actions of an N-methyl-N-2-bromoethylamino analog of oxotremorine (BR 401) in the mouse. Ringdahl B; Jenden DJ J Pharmacol Exp Ther; 1987 Feb; 240(2):370-5. PubMed ID: 3806401 [TBL] [Abstract][Full Text] [Related]
11. Alterations in behavioral responses to a cholinergic agonist in post-pubertal rats with neonatal ventral hippocampal lesions: relationship to changes in muscarinic receptor levels. Laplante F; Nakagawasai O; Srivastava LK; Quirion R Neuropsychopharmacology; 2005 Jun; 30(6):1076-87. PubMed ID: 15637638 [TBL] [Abstract][Full Text] [Related]
12. Effect of irreversible loss of muscarinic receptors on (3H)-acetylcholine release from the hippocampus. Sethy VH; Hyslop DK Neuropharmacology; 1990 Feb; 29(2):185-8. PubMed ID: 2330074 [TBL] [Abstract][Full Text] [Related]